Reviva Pharmaceuticals Holdings (RVPH) Non-Current Deffered Revenue (2018 - 2020)

Reviva Pharmaceuticals Holdings has reported Non-Current Deffered Revenue for 3 years, with the latest figure at $2.2 million in Q4 2020.

• Quarterly Non-Current Deffered Revenue changed 0.0% year-over-year to $2.2 million in Q4 2020, while the trailing twelve-month figure through Nov 2020 was $2.2 million (changed 0.0% YoY) and the FY2020 annual result came in at $2.2 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue was little changed at $2.2 million in Q4 2020 per RVPH's latest filing, from $2.2 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $2.2 million in Q3 2018 and troughed at $2.2 million in Q3 2018.
• A 3-year average of $2.2 million and a median of $2.2 million in 2018 frame the typical range for Non-Current Deffered Revenue.
• The widest YoY moves for Non-Current Deffered Revenue: up 0.0% in 2019, down 0.0% in 2019.
• Over 3 years, Non-Current Deffered Revenue stood at $2.2 million in 2018, then changed by 0.0% to $2.2 million in 2019, then changed by 0.0% to $2.2 million in 2020.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $2.2 million, $2.2 million, and $2.2 million for Q4 2020, Q3 2020, and Q2 2020 respectively.